Navigation Links
Aratana Closes $10 Million Non-Dilutive Financing with Square 1 Bank
Date:3/7/2013

KANSAS CITY, Kan. and BOSTON, March 7, 2013 /PRNewswire/ -- Aratana Therapeutics, a biopharmaceutical company developing innovative medicines for cats and dogs (companion animals), today announced it has closed on a $10 million non-dilutive financing with Square 1 Bank, a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion.  Proceeds will be used to fund general corporate purposes. 

"We are delighted to have the continued support of Square 1 Bank," stated Steven St. Peter , M.D., President and Chief Executive Officer of Aratana Therapeutics.  "We're grateful Square 1 has remained a supporter of Aratana since its inception and are eager to extend our relationship as we advance our programs."

Scott Foote , senior vice president in Square 1 Bank's Life Sciences practice, added, "We are pleased to provide Aratana with the financing solutions it needs to support future developments in the animal health market, and we look forward to the company's future success."

About Aratana Therapeutics

Aratana Therapeutics is a biopharmaceutical company positioned to deliver high quality new medicines that address significant therapeutic needs for cats and dogs (companion animals).  Aratana licenses and develops proprietary, patent-protected compounds acquired from human pharmaceutical and biotechnology companies and then develops strategies to maximize the value of the programs for the animal health market.  For more information, please visit www.aratanatherapeutics.com.

About Square 1 Bank

Square 1 Bank is a full service commercial bank dedicated exclusively to serving the financial needs of the venture capital community and entrepreneurs in all stages of growth and expansion. Square 1's expertise, focus and strong capital base provide flexible resources and unmatched support to meet our clients' needs. The bank offers tailored products and solutions aided by the latest in technological innovations. Square 1 has offices coast to coast in Austin, Boston, Denver, Durham, Los Angeles, New York, San Diego, Seattle, Silicon Valley and Washington, DC. For more information, visit www.square1bank.com

For Investors & Media:
Tiberend Strategic Advisors, Inc.
Joshua Drumm , Ph.D. / Andrew Mielach
jdrumm@tiberend.com; (212) 375-2664
amielach@tiberend.com; (212) 375-2694


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Aratana Therapeutics Adds Product Manufacturing Expertise with the Appointment of Two Senior Executives
2. Aratana Therapeutics Appoints Craig Tooman to Board of Directors
3. Aratana Therapeutics Completes $15 Million Series B Financing
4. Nasseo, Inc. Joins BioInspire™ Medical Technology Incubator, Closes Seed Funding Round
5. Biscayne Pharmaceuticals Closes $1.5 Million Financing To Advance Recent Discoveries Of Pioneering Endocrine Drug Researcher
6. Avelas Biosciences Closes $7.65 Million Series A, Advances Real-Time Tumor Visualization Technology Toward Development
7. Enviva Closes on $120 Million Senior Secured Credit Facility
8. AyoxxA Biosystems Closes Series A Financing Round
9. OncoSec Closes $7.75 Million Public Offering
10. Avaxia Biologics, Inc. Closes $4.1 Million Series A Financing to Advance Oral Antibodies for Inflammatory Bowel Disease
11. Radius Closes $27.65 Million Second Tranche of Previously Announced Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers use ... 6000i models are higher end machines that use the more unconventional z-dimension of 20mm. ... from the bottom of the cuvette holder. , FireflySci has developed several Agilent ...
(Date:6/23/2016)... June 23, 2016   Boston Biomedical , ... compounds designed to target cancer stemness pathways, announced ... granted Orphan Drug Designation from the U.S. Food ... gastric cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin ... to inhibit cancer stemness pathways by targeting STAT3, ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... and Mold) microbial test has received AOAC Research Institute approval 061601. , “This ... introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial Affairs. ...
(Date:6/23/2016)... ... 2016 , ... Supplyframe, the Industry Network for electronics hardware ... . Located in Pasadena, Calif., the Design Lab’s mission is to bring together ... built and brought to market. , The Design Lab is Supplyframe’s physical representation ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
(Date:4/26/2016)... 2016 Research and Markets has ... Market 2016-2020"  report to their offering.  , ,     ... The analysts forecast the global multimodal biometrics market ... the period 2016-2020.  Multimodal biometrics is ... as the healthcare, BFSI, transportation, automotive, and government ...
Breaking Biology News(10 mins):